...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of Clinical and Diagnostic Research >Effect of different modalities of chelation in Beta Thalassemia
【24h】

Effect of different modalities of chelation in Beta Thalassemia

机译：不同螯合方式对β地中海贫血的影响

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Beta-thalassemia major is a genetic blood disorder that results in defective production of haemoglobin.In India, almost 25 million people are carriers of beta-Thalassemia gene. Beta Thalassemia affects almost all body organ systemsand the main stay of treatment is regular blood transfusion which has its associated complications, the most important being iron overload.The iron chelators have a major role improving the life expectancy of the patients. Desferrioxamine and Deferiprone are two such chelating agents being used in patients on blood transfusion. Methods: We carried out a study on 45 Thalassemics receiving blood transfusion and divided them into three groups on the basis of iron chelators used. Their cardiac and hepatic status was assessed and correlated with serum ferretin levels that had been on chelation therapy for a minimum of six months. Results: The serum ferretin did not show a significant change in all three groups but the patients on combination therapy showed improvement in cardiac and hepatic functions. Conclusion: Although promising, a longer duration of study on a larger number of patients is required to assess the beneficial effect of combination therapy over individual chelators.
机译：严重的β地中海贫血是一种遗传性血液疾病，导致血红蛋白产生缺陷。在印度，将近2500万人是β地中海贫血基因的携带者。 β地中海贫血影响几乎所有人体器官系统，治疗的主要方法是定期输血及其相关并发症，其中最重要的是铁超负荷。铁螯合剂在改善患者预期寿命方面起着重要作用。去铁胺和去铁酮是两种用于输血患者的螯合剂。方法：我们对45种地中海贫血患者进行了输血研究，并根据所使用的铁螯合剂将其分为三组。对他们的心脏和肝脏状况进行了评估，并与螯合治疗至少六个月的血清白蛋白水平相关联。结果：血清铁蛋白在所有三组中均未显示出明显变化，但接受联合治疗的患者的心脏和肝功能有所改善。结论：尽管有希望，但需要更长的研究时间来评估更多患者，以评估联合治疗对个体螯合剂的有益作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号